Curanex Pharmaceuticals Inc (CURX) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US23126K1060

Price
5.67 USD
Market cap
7.23 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Curanex Pharmaceuticals Inc financials

Fiscal year2025
Operating income-4.24 m USD
EBIT-4.22 m USD
Net income-4.23 m USD
Diluted EPS – continuing operations-0.17 USD

Full history since 2022, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.